JAGX — Jaguar Health, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1585608 ·
Last close
$0.38
Market Cap
$1.96M
52W High
$981.75
52W Low
$0.33
ADV30
842,216
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,225,000 194,000 -7,597,000 -12,682,000 34,194,000 3,788,000 29,273,000
Mar 2026 20,247,000 19,089,000 10,182,000 8,849,000 37,434,000 7,278,000 53,186,000
Dec 2025 3,235,000 1,035,000 -20,442,000 -23,061,000 38,323,000 968,000 57,011,000
Sep 2025 3,083,000 2,551,000 -7,238,000 -9,502,000 49,472,000 3,527,000 45,113,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,542,000
Investing CF
$-256,000
Financing CF
$12,089,000
CapEx
$-215,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1639.35
As of
2026-08-23

Balance + Analyst (yfinance extras)

Retained Earnings
$-391,067,000
Inventory
$7,819,000
Receivables
$280,000
ST Investments
—
EBIT TTM
$-35,087,000
Pretax Income TTM
$-34,678,000
Interest Exp TTM
$699,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$27,815,000
EBITDA
$-23,193,000
Free Cash Flow
$-1,778,125
Enterprise Value
$14,444,846
Total Cash
$3,788,000
Total Debt
$16,651,000
Shares Out
5,168,300
Trailing EPS
$98.20
Book Value
$1.36
ROE
-548.8%
ROA
-38.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 11,511,000 -45,108,000 -53,434,000 38,323,000 57,011,000 -17,289,000 -23,686,000
Dec 2024 11,689,000 -30,831,000 -38,492,000 53,425,000 46,931,000 7,285,000 -29,384,000
Dec 2023 9,761,000 -33,920,000 -41,300,000 50,763,000 45,866,000 4,961,000 -33,242,000
Dec 2022 11,956,000 -34,415,000 -47,454,000 47,500,000 48,808,000 -657,000 -33,104,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$27,815,000
NetIncome TTM
$-52,420,000
OpCashFlow TTM
—
Assets (Latest)
$34,194,000
Forward EPS
$-5.68

Peers — same industry

TickerNameMarket CapLastDaily %
PPCB Propanc Biopharma, Inc. $1.94M $1.88 —
XRTX XORTX Therapeutics Inc. $1.93M $1.06 —
JUNS JUPITER NEUROSCIENCES, INC. $2.00M $1.52 —
ACUT Accustem Sciences Inc. $1.90M $0.12 —
SXTP 60 DEGREES PHARMACEUTICALS, INC. $1.88M $0.53 —

News headlines (Yahoo Finance, 1h cache)

Jaguar Health Inc (JAGX) Q3 2026 Earnings Call Highlights: Debt Cut by $10 Million as Rare ...
2026-11-17 21:01 · Yahoo
Jaguar Health Reports Third Quarter 2026 Financials
2026-11-16 14:00 · Yahoo
Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates
2026-11-13 14:00 · Yahoo
CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
2026-11-02 14:00 · Yahoo
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
2026-10-21 13:00 · Yahoo
Jaguar Health Provides Update Regarding Special Stock Dividend
2026-10-14 20:15 · Yahoo
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar H
2026-10-14 13:00 · Yahoo
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
2026-10-13 13:00 · Yahoo
Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances
2026-10-06 14:53 · Yahoo
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
2026-10-06 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.